-+ 0.00%
-+ 0.00%
-+ 0.00%

VivoSim Labs Expects Fiscal 2027 Revenue Growth to Exceed 500%+ Guidance

PUBT·11/19/2026 13:09:47
Listen to the news
VivoSim Labs Expects Fiscal 2027 Revenue Growth to Exceed 500%+ Guidance
  • VivoSim Labs expects fiscal 2027 revenue to exceed its July 15 guidance for growth of more than 500%.
  • A seven-figure testing agreement with a top-10 global pharmaceutical company is expected to push revenue beyond that forecast.
  • Agreement revenue is expected in the third and fourth quarters, ending Dec. 31 and March 31, respectively.
  • The liver and intestinal toxicology program is underway, with testing expected to become part of the customer's regular preclinical workflow.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VivoSim Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611190805PRIMZONEFULLFEED9881038) on November 19, 2026, and is solely responsible for the information contained therein.